SyntheticMR
SyntheticMR Receives Regulatory Approval for SyMRI 15 in Switzerland
This milestone enables the company to market and distribute SyMRI 15 across the Swiss healthcare sector, marking a significant stride in SyntheticMR's strategic growth within Europe.
SyMRI 15 is a groundbreaking imaging solution that revolutionizes conventional magnetic resonance imaging (MRI) practices. Clinically validated through an extensive multi-center study involving several top-tier institutes in the United States, SyMRI 15 has demonstrated the capability to replace traditional 3D imaging techniques. The study highlighted significant enhancements in efficiency and throughput, without compromising diagnostic accuracy.
"Entering the Swiss market is a pivotal moment for SyntheticMR," said Ulrik Harrysson, CEO of SyntheticMR AB. "Switzerland is renowned for its high standards in healthcare, and the approval of SyMRI 15 here underscores the quality and efficacy of our technology. We are committed to partnering with Swiss healthcare providers to transform medical diagnostics and improve patient outcomes."
| Datum | 2024-10-02, kl 10:15 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!